<DOC>
	<DOCNO>NCT02105662</DOCNO>
	<brief_summary>The purpose study assess efficacy safety grazoprevir ( MK-5172 ) 100 mg combination elbasvir ( MK-8742 ) 50 mg treatment chronic hepatitis C virus ( HCV ) participants co-infected human immunodeficiency virus ( HIV ) . The primary hypothesis percentage participant receive grazoprevir + elbasvir achieve Sustained Virologic Response 12 week therapy ( SVR12 ) great 70 % .</brief_summary>
	<brief_title>An Efficacy Safety Study Grazoprevir ( MK-5172 ) + Elbasvir ( MK-8742 ) Treatment Chronic Hepatitis C Virus Participants Who Are Co-Infected With Human Immunodeficiency Virus : C-EDGE CO-INFXN ( MK-5172-061 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<criteria>Documented chronic HCV genotype ( GT ) 1 , GT4 , GT6 infection evidence nontypeable mixed GT infection ( positive antiHCV antibody , HCV RNA , list GTs least 6 month prior screen must confirm screen lab result ) Treatment naïve antiHCV treatment HIV1 infection document laboratory test Currently naïve treatment antiretroviral therapy ( ART ) plan initiate ART study OR HIV ART least 8 week prior study entry Has experience alteration ( ) HIV therapy within 4 week randomization Has least one viable antiretroviral regimen alternative beyond current regimen event HIV virologic failure development antiretroviral drug resistance Participants reproductive potential must agree remain abstinent heterosexual activity OR use ( partner use ) acceptable contraception heterosexual activity receive study drug 14 day last dose study drug . Evidence decompensated liver disease manifest presence history ascites , esophageal gastric variceal bleeding , hepatic encephalopathy sign symptom advance liver disease Coinfected hepatitis B virus History malignancy &lt; =5 year prior study start except adequately treat basal cell squamous cell skin cancer situ cervical cancer evaluation active suspected malignancy Taking plan take HIV therapy include ritonavirboosted unboosted protease inhibitor , efavirenz etravirine Currently participate participate study investigational compound within 30 day study start willing refrain participate another study study Clinicallyrelevant drug alcohol abuse within 12 month study start Pregnant , breast feeding , expect conceive donate egg Day 1 study throughout treatment 14 day last dose study medication , longer dictate local regulation Organ transplant ( include hematopoietic stem cell transplant ) cornea hair Poor venous access History gastric surgery ( e.g. , staple , bypass ) history malabsorption disorder ( e.g. , celiac sprue disease ) Medical condition requiring , likely require , chronic systemic administration corticosteroid study History opportunistic infection 6 month prior study start Use HIV drug dual nucleoside reverse transcriptase inhibitor ( NRTI ) backbone tenofovir abacavir either emtricitibine lamivudine PLUS raltegravir ( dolutegravir rilpivirine )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>